What Progenetics does

ProGenetics Ltd. is an Israeli precision oncology company that serves as the in-country distributor and clinical coordinator of advanced cancer genetic testing for all Israeli hospitals and treating physicians. Founded in 2015 by Dr. Yoav Menaster and Dror Kartesh, the company represents approximately 15 world-leading US laboratories in Israel — including Natera, Caris Life Sciences, Decipher Biosciences (Veracyte), Pacific Edge Diagnostics, Biotheranostics (Hologic), BioReference, Fulgent Genetics, and Biodesix — offering what it describes as the broadest portfolio of advanced cancer genetic tests available in the Israeli market.

The company's product portfolio spans seven core diagnostic tests across multiple cancer types and sample modalities: tissue-based comprehensive molecular profiling (Caris MI Profile analyzing 700+ DNA genes, 20,000+ RNA transcripts and protein IHC at 1,500X sequencing depth; Decipher 22-gene RNA expression for prostate cancer), liquid biopsy (Caris Liquid Biopsy with Whole Exome + Transcriptome sequencing and CHIP filtering at 8,000X depth achieving 93.8% tissue concordance; Signatera personalized tumor-informed ctDNA MRD test at 100,000X depth), prostate risk assessment (4Kscore kallikrein panel with 99% NPV), bladder cancer detection (Cxbladder 5-mRNA urine test with >98% NPV), and breast cancer recurrence risk (BCI 11-gene RT-PCR assay for endocrine therapy benefit and late recurrence years 5–10). All tests are performed in CAP/CLIA-certified US partner laboratories; Progenetics handles sample retrieval from Israeli hospital pathology departments, international logistics, result delivery to treating physicians, and insurance reimbursement support.

Progenetics operates a sales-led B2B2C model, charging unit prices per test with pay-as-you-go billing. Reimbursement is available through Israeli health funds (Clalit, Meuhedet, Leumit), private insurance, and Medicare for eligible patients. The company is privately held with no disclosed external funding, parent, or subsidiaries; ownership appears founder-controlled. It holds ISO 9001:2015, ISO/IEC 27001, and ISO 27799 certifications, and its underlying tests carry guideline endorsements from NCCN, ASCO, and EAU. Headquarters are in Azor, Israel, with a small named team led by CEO Dr. Yoav Menaster.

Name

Progenetics

Legal name

ProGenetics Ltd.

Website

https://progenetics.co.il

Company type

Private

Founded year

2015

Operating status

Operating

Short description

Progenetics is an Israeli precision oncology company that distributes and coordinates advanced cancer genetic tests from approximately 15 US laboratories for Israeli hospitals, oncologists, and patients across all nationwide hospitals.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Population Genomics & Preventive Precision Health Programs (HLAAANAL)

Keywords

• Cancer genetic testing
• Molecular diagnostics
• Precision oncology services
• Tumor profiling tests
• Personalized cancer medicine

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Genetic Testing Services: Progenetics acts as a distributor and coordinator for advanced genetic cancer tests performed by partner laboratories in the United States. Patients or their insurers/health funds pay for the tests, with Progenetics coordinating sample collection, shipping to US labs, and delivery of results to Israeli treating physicians. Tests are priced individually per test type, with reimbursement available through Israeli health funds (Clalit, Meuhedet, Leumit) and private insurance.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Progenetics is an Israeli healthcare company that distributes and coordinates advanced genetic cancer tests from approximately 15 leading US partner laboratories (including Natera, Caris Life Sciences, Decipher Biosciences, Pacific Edge, and Biotheranostics) to Israeli hospitals, oncologists, and patients. The company manages the end-to-end logistics of sample collection, international shipping to certified US labs, and delivery of results to treating physicians. Its portfolio spans molecular profiling, MRD detection, liquid biopsy, and genomic risk assessment tests covering solid tumors, breast cancer, prostate cancer, and bladder cancer.

Product overview

Progenetics is a genetic testing company offering a portfolio of seven distinct diagnostic tests for personalized cancer medicine. The portfolio includes tissue-based tests (Caris MI Profile, Decipher, BCI), liquid biopsy tests (Caris Liquid Biopsy, Signatera), urine-based tests (Cxbladder), and blood-based risk assessment (4Kscore). Tests are performed at partner laboratories in the United States, including Caris Life Sciences, Natera, Decipher Biosciences, Pacific Edge, and Biotheranostics. The company acts as a distributor/representative in Israel for approximately 15 international laboratories, providing the broadest range of genetic tests available in the Israeli market.

Differentiator

Problem solved

Functional benefit

Products and services

• Caris MI Profile Comprehensive molecular profiling test for solid tumors that combines Whole Exome Sequencing, Whole Transcriptome Sequencing, and protein expression profiling (IHC) at 1,500X sequencing depth to guide precision oncology treatment decisions. Intended for oncologists and cancer-treating physicians.
• Signatera Personalized ctDNA test for minimal residual disease (MRD) detection and recurrence monitoring in cancer patients, tracking 16 patient-specific tumor mutations in blood samples at 100,000X sequencing depth. Recognized by NCCN for MRD monitoring.
• 4Kscore Blood-based prostate cancer risk assessment test measuring four kallikrein biomarkers with a clinical algorithm to produce a personalized risk score, helping avoid approximately 40% of unnecessary prostate biopsies. Recommended by NCCN and EAU guidelines.
• Decipher Genomic test analyzing 22 cancer-related genes via RNA expression to produce a risk score (low, intermediate, high) predicting prostate cancer aggressiveness, metastasis, and recurrence after prostatectomy. Supported by 70+ peer-reviewed studies and included in NCCN guidelines.
• Cxbladder Non-invasive urinary genomic test measuring five mRNA biomarkers via RT-PCR for bladder cancer detection and surveillance, with >98% accuracy in excluding bladder cancer when negative. The only test in international guidelines for excluding bladder cancer in micro-hematuria at reliability level A.
• Caris Liquid Biopsy Liquid biopsy using Whole Exome Sequencing and Whole Transcriptome Sequencing from blood samples at 8,000X depth to characterize solid tumors without invasive tissue biopsy, with 93.8% tissue concordance, CHIP filtering, and germline analysis.
• BCI (Breast Cancer Index) Gene expression test analyzing 11 genes to predict benefit from extended endocrine therapy and assess late recurrence risk (years 5–10) in HR+ early-stage breast cancer. Included in ASCO and NCCN guidelines.

Quantifiable outcome

• 4Kscore prevents approximately 40% of unnecessary prostate biopsies with 99% negative predictive value for aggressive prostate cancer
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Natera, Inc.coreTechnology or IntegrationProgenetics represents Natera's Signatera ctDNA test in Israel. Signatera is a personalized tumor-informed assay for minimal residual disease (MRD) detection and recurrence monitoring across multiple cancer types. Progenetics coordinates sample collection and international shipping of tumor tissue and blood samples to Natera's US laboratory.
• Caris Life SciencescoreTechnology or IntegrationProgenetics represents Caris MI Profile (comprehensive molecular profiling) and Caris Liquid Biopsy in Israel. Caris performs multi-omic tumor profiling (DNA, RNA, protein) with the broadest genomic coverage available. Tests are FDA-approved and performed in CAP/CLIA-certified US laboratories.
• Decipher Biosciences (Veracyte)coreTechnology or IntegrationProgenetics represents Decipher genomic tests for prostate cancer in Israel. Decipher analyzes 22 genes via RNA expression profiling to predict cancer aggressiveness and guide treatment decisions. Supported by over 70 peer-reviewed studies and included in NCCN guidelines.
• Pacific Edge DiagnosticscoreTechnology or IntegrationProgenetics represents Cxbladder genomic urine test in Israel. Cxbladder is a non-invasive test measuring five mRNA biomarkers for bladder cancer detection and surveillance, performed in CLIA & CAP certified US laboratories.
• Biotheranostics (Hologic Company)coreTechnology or IntegrationProgenetics represents the Breast Cancer Index (BCI) test by Biotheranostics in Israel. BCI analyzes 11 genes to predict benefit from extended endocrine therapy and late recurrence risk in HR+ early-stage breast cancer. Included in ASCO and NCCN guidelines.
• Weizmann Institute of ScienceminorStrategic or Co-development PartnerProgenetics collaborates with the Weizmann Institute of Science on academic research in personalized cancer medicine and molecular profiling.
• Tel Aviv UniversityminorStrategic or Co-development PartnerProgenetics collaborates with Tel Aviv University on academic research in the field of personalized cancer medicine and genetic testing.
• Hebrew University of JerusalemminorStrategic or Co-development PartnerProgenetics collaborates with Hebrew University on academic research in personalized cancer medicine and genomic testing.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Novamed Ltd. Israeli medical device and diagnostics distributor. Comparable as a domestic Israeli distributor bringing international advanced medical technologies to Israeli hospitals and physicians.
• Medison Pharma: Israeli specialty pharmaceutical and diagnostics distributor with exclusive partnerships for innovative therapies. Comparable distribution model bringing global healthcare products to the Israeli market through hospital and physician channels.

Broad incumbents

• Natera: US-based genetics company with leading cell-free DNA and MRD tests including Signatera. Progenetics is Natera's Israeli channel partner, making Natera the upstream lab partner whose go-to-market model Progenetics replicates at country scale.
• Veracyte (Decipher Biosciences): US-based genomic diagnostics company that acquired Decipher Biosciences. Progenetics is its Israeli distribution partner for the Decipher prostate cancer test, making Veracyte a directly comparable but much larger incumbent in the same product category.
• Caris Life Sciences: US-based molecular science company developing MI Profile and Caris Liquid Biopsy. Progenetics represents Caris in Israel, so Caris is the upstream lab counterpart providing the multi-omic profiling Progenetics distributes.
• NeoGenomics Laboratories: US-based oncology-focused clinical laboratory offering comprehensive cancer genetic testing services. Comparable in the underlying molecular oncology diagnostics portfolio Progenetics distributes, though at much larger scale and with proprietary lab capability.
• Exact Sciences (Genomic Health): US-based molecular diagnostics company with leading oncology tests (Oncotype DX). Comparable as the developer of guideline-endorsed cancer genomic tests that Progenetics-like distributors channel into international markets.

Emerging players

• Guardant Health: US-based precision oncology liquid biopsy company. Comparable as a developer of advanced cancer genomic tests that increasingly reach international markets through regional distribution partnerships analogous to Progenetics' model.

Direct peers

• OncoDNA: Belgium-based molecular diagnostics company distributing comprehensive oncology genetic tests across Europe and beyond. Highly comparable as a regional specialty distributor/coordinator of advanced cancer genomics, serving hospitals and oncologists with a multi-lab portfolio.
• Pacific Edge Diagnostics: New Zealand-based cancer diagnostics company commercializing Cxbladder. Progenetics is Pacific Edge's Israeli distributor, making Pacific Edge a direct upstream partner with a comparable international-distribution go-to-market approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Progenetics